EGFR and lung cancer: The treatment of lung cancer has been dramatically improved in the past 17 years with the discovery of driver oncogenes and the development of molecularly targeted drugs that bind them, including osimertinib for mutant EGFR or crizotinib for ROS1 fusions1,2.